Last reviewed · How we verify

Caplyta — Competitive Intelligence Brief

Caplyta (LUMATEPERONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical Antipsychotic [EPC]. Area: Neuroscience.

marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Caplyta (LUMATEPERONE) — Intra-Cellular. Caplyta works by binding to the 5-hydroxytryptamine receptor 2A, which helps to regulate dopamine and serotonin levels in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Caplyta TARGET LUMATEPERONE Intra-Cellular marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A 2019-01-01
Nuplazid PIMAVANSERIN Acadia Pharms Inc marketed Atypical Antipsychotic 5-hydroxytryptamine receptor 2A 2016-01-01
Latuda LURASIDONE Sunovion Pharms Inc marketed Atypical Antipsychotic 5-hydroxytryptamine receptor 2A 2010-01-01
Fanapt ILOPERIDONE Vanda Pharms Inc marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A 2009-01-01
Remeron mirtazapine Generic (originally Organon/MSD) marketed NaSSA (Noradrenergic and specific serotonergic antidepressant) 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1996-06-14
Effexor venlafaxine Generic (originally Wyeth/Pfizer) marketed SNRI (Serotonin-norepinephrine reuptake inhibitor) 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1993-12-28
Alimix CISAPRIDE marketed High Risk QT Prolonging Agents 5-hydroxytryptamine receptor 2A 1993-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical Antipsychotic [EPC] class)

  1. · 2 drugs in this class
  2. AbbVie · 1 drug in this class
  3. Alkermes Inc · 1 drug in this class
  4. Eli Lilly · 1 drug in this class
  5. Hisamitsu · 1 drug in this class
  6. Intra-Cellular · 1 drug in this class
  7. Jazz Pharmaceuticals · 1 drug in this class
  8. Johnson & Johnson (Janssen) · 1 drug in this class
  9. Otsuka · 1 drug in this class
  10. Vanda Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Caplyta — Competitive Intelligence Brief. https://druglandscape.com/ci/lumateperone. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: